Watson Biotech (300142.SZ): Bivalent HPV Vaccine Cyrin Bottle Specification Obtains Marketing License in Tanzania

Zhitong Finance App News, Watson Biotech (300142.SZ) issued an announcement. The bivalent human papillomavirus vaccine (Pichi yeast) (trade name “WALRINVAX”, hereinafter referred to as “bivalent HPV vaccine”) produced by the company's subsidiary Yuxi Zerun Biotechnology Co., Ltd. (hereinafter referred to as “Yuxi Zerun”) recently received a “Drug Registration Certificate” issued by the Tanzania Medicines and Medical Devices Authority (Tanzania MedicinesandMedical Devices Authority), double price The HPV vaccine has obtained marketing approval for the vials of the HPV vaccine in Tanzania.

The Yuxi Zerun bivalent HPV vaccine is mainly used to prevent related diseases caused by high-risk HPV types 16 and 18, such as cervical cancer, grade 2 and grade 3 cervical intraepithelial neoplasia (CIN2/3), and cervical adenocarcinoma in situ (AIS). The vaccine was officially marketed in 2022 and was pre-certified by the World Health Organization (WHOPQ) in August 2024.